Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated March 28, 2023, reports interim results from Part 1 of the Phase III RUBY clinical trial. The trial investigates Jemperli (dostarlimab) combined with standard-of-care chemotherapy versus chemotherapy plus placebo in adult patients with primary advanced or recurrent endometrial cancer. The data was presented at the ESMO Virtual Plenary and SGO Annual Meeting and published in The New England Journal of Medicine.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical trial update and does not contain financial statements.
Material Changes and Clinical Results
The filing details statistically significant improvements in Progression-Free Survival (PFS) for the dostarlimab plus chemotherapy arm compared to placebo plus chemotherapy:
- dMMR/MSI-H Population: 72% reduction in the risk of disease progression or death (Hazard Ratio 0.28; P<0.0001). At 24 months, PFS was 61.4% versus 15.7%.
- Overall Population: 36% reduction in the risk of disease progression or death (Hazard Ratio 0.64; P<0.0001). At 24 months, PFS was 36.1% versus 18.1%.
- Overall Survival (OS): A clinically meaningful trend was observed in the overall population (Hazard Ratio 0.64; P=0.0021), though statistical significance was not reached at 33% maturity.
Guidance, Outlook, and Risks
Regulatory Outlook: GSK plans regulatory submissions for this indication in the first half of 2023. Jemperli is not currently approved for use in combination with chemotherapy for this specific indication, though it holds accelerated approval in the US for dMMR recurrent or advanced solid tumors.
Safety Profile: The safety profile was generally consistent with known profiles of the individual agents. Severe and serious treatment-emergent adverse events were approximately 10% higher in the dostarlimab arm. Immune-related adverse events occurred in 38.2% of the dostarlimab arm versus 15.4% in the placebo arm, with endocrinopathies and skin reactions being the most frequent.
Risks: The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in the 2022 Form 20-F, including impacts from the COVID-19 pandemic.
Investor Verification Checklist
- Verify the timeline for regulatory submissions planned for the first half of 2023.
- Confirm the current approval status of Jemperli in the US and EU for combination therapy in endometrial cancer.
- Review the full safety data regarding immune-related adverse events and discontinuation rates (17.4% in dostarlimab arm vs 9.3% in placebo arm).
- Monitor the maturity of the Overall Survival analysis, which was at 33% at the time of this interim report.